Skip to content

Reference

Evidence

CompoundsSubstances with curated findings
OutcomesMeasured endpoints
ProteinsTransporters and enzymes
InteractionsPairs that share biology
PapersEvery paper a finding cites
ArticlesReadings of the evidence

Chemistry

ReactionsRhea and Human-GEM, by subsystem
ReachWhat a compound can become

Reference layer

PathwaysReactions grouped under one name
ProcessesWhat proteins are annotated as doing
AnatomyTissues, by what is expressed there
Cell typesCells, by what is expressed there
OrganismsSpecies a compound is prepared from
MaterialsSubstances that are not one molecule
AssessmentsRegulatory determinations, transcribed
DiseasesFeatures, genes, and where each sits

Atlas Graph Twin Access

Search the graph

Reference

Evidence

Compounds
Outcomes
Proteins
Interactions
Papers
Articles

Chemistry

Reactions
Reach

Reference layer

Pathways
Processes
Anatomy
Cell types
Organisms
Materials
Assessments
Diseases

Atlas Graph Twin Access

Loading the page.

Catalyst

Computational infrastructure for human biology, built on a provenance-aware knowledge graph. Findings retain their sources; research and simulation are the next layers.

The graph

Compounds
Outcomes
Proteins
Atlas
Interactions
Papers
Articles
Graph
Search

Reference layer

Pathways
Processes
Anatomy
Cell types
Organisms
Materials
Assessments
Diseases
Reactions
Reach

How it works

Mission
Method
Twin
How to read the evidence
Sources and licences

Build on it

Access
In your assistant
For agents
Query the graph
Bulk export

A reference for what the literature reports. Not medical advice.

© 2026 CatalystPrivacy TermsReference data under the licences listed on the attribution page.

Papers/PMID:26252777

Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.

PloS one2015The record

1 finding · 1 compound · 1 endpoint

berberine

What it reported

How to read these marks

What moved

1 finding

berberine — accumulates in liver
Very limitedEvidence strength: very limited. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding
“As shown in Fig 4, BBR and its metabolites were distributed in the liver.”
Quoted verbatim from Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease..
Study

animal · not in humans
Dose

single oral dose 200 mg/kg
Population

High-fat-diet-induced NAFLD male Sprague-Dawley rats, liver sampled 0 to 48 h after a single oral dose
Efficacy of Berberine in Patients with Non-Alcoholic Fatty Liver Disease.2015PMID:26252777Permalink